Vinorelbine ditartaric acid belongs to the family of vinca alkaloid anti-cancer drugs. It comes from the semi-synthesis of plant-based compounds, which gives it unique therapeutic properties for treating various types of cancers, especially non-small cell lung cancer and breast cancer. Experts in pharmaceutical chemistry track down sources for this compound with a strong focus on both effectiveness and safety, since its chemistry packs potent biological activity. The structure consists of vinorelbine as the main active agent, married molecularly to ditartaric acid, a salt-forming agent that stabilizes the drug for better absorption. Most importantly, this combination changes both the solubility and the handling profile, which plays a real-life role in storage, transport, and application throughout supply chains and hospitals worldwide.
Looking at its raw material form, vinorelbine ditartaric acid shows up as a solid, sometimes as powder, flakes, or crystalline pearls, based on batch processing. Standard lab reports determine density close to 1.2 g/cm3, but this shifts with humidity and packaging—something people who manage pharmaceutical inventories know too well. Melting points range above 200°C, a reflection of its solid chemistry, and mark its stability during regular storage. Color runs off-white to pale yellow, and every time a fresh batch arrives, labs perform checks to catch any impurity or off-color, since that might signal a degradation issue or source contamination. At room temperature, solubility in water tends toward moderate, which allows compounding professionals to dissolve or dilute it in liters of solution for IV administration. Chemists work hard to control pH during this stage so as to keep the active principle stable.
This compound bears a complex formula involving several carbon, hydrogen, nitrogen, and oxygen atoms. The molecular formula stands as C45H54N4O8·C4H6O6, underlining the combination of vinorelbine and tartaric acid. Every lab supervisor pays attention to molecular weight—close to 969.1 g/mol. The three-dimensional structure consists of fused ring systems, plenty of chiral centers, and bulky ester linkages, leading to its select medicinal properties and challenges in synthetic production. The dual nature of the molecule—vinorelbine’s larger core and the tartaric acid tail—contributes to its solubility and bioavailability.
Suppliers list the content of vinorelbine ditartaric acid in terms of purity, sometimes reaching above 98% by HPLC analysis, and always provide a full data sheet on all trace impurities or byproducts. Since the pharmaceutical industry works under tight regulation, each container gets marked with an HS Code—usually 2934.99, under heterocyclic compounds. Regulatory agencies insist on traceability and evidence of batch testing, requiring these standards before any shipment leaves the warehouse. Certificates of analysis cover appearance, melting range, specific rotation, and residual solvents, and all of this gets archived to build trust with clinical buyers and regulatory auditors alike.
Chemical safety ranks top priority with vinorelbine ditartaric acid. This molecule is potent, both beneficial for cancer treatment and harmful if mishandled. Skin contact, inhalation, or accidental ingestion carry serious health consequences, including acute toxicity. Lab staff and pharmacists receive special training and gear up with gloves, gowns, and goggles before opening even small-scale sample bottles. Chemical hazard sheets mark this as harmful, requiring dedicated workspaces, often inside certified chemical fume hoods or biologic safety cabinets. Storage containers bear clear hazardous material labels, and everyone in the supply line treats this with respect, having seen first-hand what accidental exposure means. Spills trigger emergency procedures, with cleanup involving absorbent materials and proper disposal routines—nothing gets left to chance. Any environmental discharge must stay below strict regulatory levels, as small traces could cause damage to aquatic or terrestrial life.
At the earliest production stages, vinorelbine ditartaric acid’s manufacture starts by pulling together natural vinca alkaloid sources—often leaves of Catharanthus roseus (Madagascar periwinkle)—and subjecting these to controlled extraction and chemical modification. Several chemical suppliers contribute different quality standards, and procurement specialists spend plenty of effort ensuring compliance with international conventions for sustainable sourcing. Supply chain disruptions sometimes occur, especially when political instability or export restrictions hit key raw material regions, so companies develop backup strategies, maintaining stocks and qualifying alternative suppliers. Issues of purity and consistency get managed with repeated in-house and third-party testing before final approval.
With every shipment and every use in the clinic, staff face a tough balance: harness the cancer-fighting ability of vinorelbine ditartaric acid while neutralizing the severe hazards posed by handling such chemicals. Researchers aim for cleaner, greener synthetic routes in response to both regulatory pressure and environmental stewardship. Waste management around this chemical relies on disciplined, science-backed protocols, using closed systems and validated neutralization routes. Hospitals have set strict policies for disposal, plus ongoing education for staff at all levels, reducing both workplace risk and release to the environment. Some manufacturers invest in continuous process improvements, switching out older, more polluting solvents and seeking circular economy partners to minimize leftover chemical and packaging waste. From my own experience working around research teams in pharmaceutical settings, I have witnessed a deep sense of responsibility—discussions rarely gloss over risks, and compliance forms part of every conversation. Attempts to create biosimilar versions of this molecule require even closer analysis, especially as patient safety and public trust remain non-negotiable.
To sum up the core aspects, vinorelbine ditartaric acid comes as a solid—most often white to pale yellow powder, flakes, or crystal forms—with density around 1.2 g/cm3. Its molecular formula is C45H54N4O8·C4H6O6, and molecular weight edges close to 969.1 g/mol. The melting point lives well above 200°C, and the product dissolves steadily in water and compatible solvents prepared for injection or IV administration. Handling needs strict laboratory and clinical precautions, as its toxicity is well-documented. For international trade, the HS Code 2934.99 applies. Material comes sourced from plant-derived and synthetic routes blended through careful chemical processing. Properties like purity levels, density, and particle size get monitored tightly to meet drug manufacturing requirements. The hazards surrounding raw material and finished form require ongoing vigilance in storage, use, and disposal, keeping both medical professionals and support staff safe.
Providing high-quality chemical products and logistics solutions for global trade partners.
